Nuformix’s NXP002 for IPF Shows Promise in Preclinical Studies

Nuformix’s NXP002 for IPF Shows Promise in Preclinical Studies

312927

Nuformix’s NXP002 for IPF Shows Promise in Preclinical Studies

NXP002, Nuformix’s experimental inhaled therapy for idiopathic pulmonary fibrosis (IPF), achieves significant levels in the lungs and lowers the production of molecules that promote scarring, according to preclinical studies involving rats, the company announced. “We’re delighted with the positive readout of this data so far and it further cements our belief in NXP002 as a valuable asset,” Anne Brindley, PhD, Nuformix’s CEO, said in a press release. “We have previously reported data on the activity…

You must be logged in to read/download the full post.